By Dr. Chinta Sidharthan New research highlights how elevated levels of the iron-regulating hormone hepcidin contribute to ...

The researchers note that roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor, which targets inflammatory pathways central ...

Mice showing the first symptoms of a psoriasis-like phenotype were injected with anti-VEGF antibodies (n = 12) or an IgG isotype control (n = 8) every 48 hours for 8 days. By days 23–24, skin ...

AbbVie has announced that it will be expanding its immunology capabilities by acquiring Capstan Therapeutics for up to $2.1bn ...

Armed with the latest biological knowledge and cutting-edge computational techniques—and, of course, investor dollars—these ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

For patients with psoriasis and Type 2 diabetes, the risk of developing chronic kidney disease (CKD) continued to rise ...

A new Delphi consensus led by the National Psoriasis Foundation proposes a standardized definition of on-treatment remission ...

Psoriasis is a chronic autoimmune condition that mainly affects the skin. When you have psoriasis, your immune system sends ...

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

Tumor necrosis factor (TNF) inhibitor therapy was effective in reducing the likelihood that psoriasis would progress to ...

How Does Psoriasis Increase Your Risk of Developing Other Conditions? Psoriasis is much more than a skin condition. Though it ...